Abstract：【Objective】To observe the expression of DKK-1, β-catenin and caspase 3 in patients with diffuse large B-cell lymphoma (DLBCL) and analyze the influencing factors. 【Methods】The patients with DLBCL who were treated in our hospital from February 2014 to August 2019were enrolled. The expressions of DKK-1, β-catenin and caspase 3 in cancer tissues and paracancerous tissues of patients with DLBCL were detected and their effects were analyzed. 【Results】The positive expression rates of DKK-1, β-catenin and caspase 3 in cancer tissues of DLBCL patients were significantly higher than those in cancer adjacent tissues. The difference was statistically significant (P<0.05). The clinical stage in Ⅲ+Ⅳ, PS score ≥2, and IDH increased. The positive expression rates of DKK-1, β-catenin and caspase 3 in DLBCL patients with clinical stage Ⅲ+Ⅳ, PS (performance status) score ≥2, high IDH (isocitrate dehydrogenase), and high risk of IPI (international prognostic index) were much higher (P<0.05). There were no significant differences in the positive expression rates of DKK-1, β-catenin and caspase 3 in patients with different ages and genders. DKK- patients with DLBCL 1. Multivariate logistica repression showed that clinical stage and IDH were the factors that affected the expression of DKK-1, β-catenin and caspase 3 expression in DLBCL patients (OR=4.865, 5.013). 【Conclusion】The positive expression rates of DKK-1, β-catenin and caspase 3 in patients with diffuse large B-cell lymphoma are high, which are affected by clinical stage and IDH.
丁凤娇, 曹洪友. 弥漫大B细胞淋巴瘤患者DKK-1、β-catenin、Caspase 3蛋白表达水平的变化及意义[J]. 医学临床研究, 2021, 38(10): 1560-1562.
DING Feng-Jiao, CAO Hong-you. Significance of DKK-1, β-catenin and Caspase 3 Protein Expression in Patients with DLBCL. JOURNAL OF CLINICAL RESEARCH, 2021, 38(10): 1560-1562.
2021, Vol. 38 
